139 related articles for article (PubMed ID: 12391605)
1. Remarkable increase in the concentration of 8-hydroxyguanosine in cerebrospinal fluid from patients with Alzheimer's disease.
Abe T; Tohgi H; Isobe C; Murata T; Sato C
J Neurosci Res; 2002 Nov; 70(3):447-50. PubMed ID: 12391605
[TBL] [Abstract][Full Text] [Related]
2. Homocysteine may contribute to pathogenesis of RNA damage in brains with Alzheimer's disease.
Isobe C; Abe T; Terayama Y
Neurodegener Dis; 2009; 6(5-6):252-7. PubMed ID: 19940460
[TBL] [Abstract][Full Text] [Related]
3. Alteration of 8-hydroxyguanosine concentrations in the cerebrospinal fluid and serum from patients with Parkinson's disease.
Abe T; Isobe C; Murata T; Sato C; Tohgi H
Neurosci Lett; 2003 Jan; 336(2):105-8. PubMed ID: 12499051
[TBL] [Abstract][Full Text] [Related]
4. Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy.
Kikuchi A; Takeda A; Onodera H; Kimpara T; Hisanaga K; Sato N; Nunomura A; Castellani RJ; Perry G; Smith MA; Itoyama Y
Neurobiol Dis; 2002 Mar; 9(2):244-8. PubMed ID: 11895375
[TBL] [Abstract][Full Text] [Related]
5. Altered kallikrein 7 and 10 concentrations in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia.
Diamandis EP; Scorilas A; Kishi T; Blennow K; Luo LY; Soosaipillai A; Rademaker AW; Sjogren M
Clin Biochem; 2004 Mar; 37(3):230-7. PubMed ID: 14972646
[TBL] [Abstract][Full Text] [Related]
6. Reduced CSF PLTP activity in Alzheimer's disease and other neurologic diseases; PLTP induces ApoE secretion in primary human astrocytes in vitro.
Vuletic S; Peskind ER; Marcovina SM; Quinn JF; Cheung MC; Kennedy H; Kaye JA; Jin LW; Albers JJ
J Neurosci Res; 2005 May; 80(3):406-13. PubMed ID: 15795933
[TBL] [Abstract][Full Text] [Related]
7. Increase in the oxidized/total coenzyme Q-10 ratio in the cerebrospinal fluid of Alzheimer's disease patients.
Isobe C; Abe T; Terayama Y
Dement Geriatr Cogn Disord; 2009; 28(5):449-54. PubMed ID: 19907182
[TBL] [Abstract][Full Text] [Related]
8. BDNF serum and CSF concentrations in Alzheimer's disease, normal pressure hydrocephalus and healthy controls.
Laske C; Stransky E; Leyhe T; Eschweiler GW; Maetzler W; Wittorf A; Soekadar S; Richartz E; Koehler N; Bartels M; Buchkremer G; Schott K
J Psychiatr Res; 2007 Aug; 41(5):387-94. PubMed ID: 16554070
[TBL] [Abstract][Full Text] [Related]
9. Increased acidic fibroblast growth factor concentrations in the serum and cerebrospinal fluid of patients with Alzheimer's disease.
Mashayekhi F; Hadavi M; Vaziri HR; Naji M
J Clin Neurosci; 2010 Mar; 17(3):357-9. PubMed ID: 20079650
[TBL] [Abstract][Full Text] [Related]
10. Differential acetylcholine and choline concentrations in the cerebrospinal fluid of patients with Alzheimer's disease and vascular dementia.
Jia JP; Jia JM; Zhou WD; Xu M; Chu CB; Yan X; Sun YX
Chin Med J (Engl); 2004 Aug; 117(8):1161-4. PubMed ID: 15361288
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid, serum and plasma protein oxidation in Alzheimer's disease.
Korolainen MA; Pirttilä T
Acta Neurol Scand; 2009 Jan; 119(1):32-8. PubMed ID: 18547271
[TBL] [Abstract][Full Text] [Related]
12. Macrophage migration inhibitory factor in mild cognitive impairment and Alzheimer's disease.
Popp J; Bacher M; Kölsch H; Noelker C; Deuster O; Dodel R; Jessen F
J Psychiatr Res; 2009 May; 43(8):749-53. PubMed ID: 19038405
[TBL] [Abstract][Full Text] [Related]
13. Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease.
Galimberti D; Schoonenboom N; Scheltens P; Fenoglio C; Bouwman F; Venturelli E; Guidi I; Blankenstein MA; Bresolin N; Scarpini E
Arch Neurol; 2006 Apr; 63(4):538-43. PubMed ID: 16606766
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer's disease.
Montine TJ; Markesbery WR; Morrow JD; Roberts LJ
Ann Neurol; 1998 Sep; 44(3):410-3. PubMed ID: 9749613
[TBL] [Abstract][Full Text] [Related]
15. Metal concentrations in plasma and cerebrospinal fluid in patients with Alzheimer's disease.
Gerhardsson L; Lundh T; Minthon L; Londos E
Dement Geriatr Cogn Disord; 2008; 25(6):508-15. PubMed ID: 18463412
[TBL] [Abstract][Full Text] [Related]
16. Increase of total homocysteine concentration in cerebrospinal fluid in patients with Alzheimer's disease and Parkinson's disease.
Isobe C; Murata T; Sato C; Terayama Y
Life Sci; 2005 Aug; 77(15):1836-43. PubMed ID: 15935398
[TBL] [Abstract][Full Text] [Related]
17. CSF cortisol in Alzheimer's disease and mild cognitive impairment.
Popp J; Schaper K; Kölsch H; Cvetanovska G; Rommel F; Klingmüller D; Dodel R; Wüllner U; Jessen F
Neurobiol Aging; 2009 Mar; 30(3):498-500. PubMed ID: 17716786
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid neuron-specific enolase: a further marker of Alzheimer's disease?
Palumbo B; Siepi D; Sabalich I; Tranfaglia C; Parnetti L
Funct Neurol; 2008; 23(2):93-6. PubMed ID: 18671910
[TBL] [Abstract][Full Text] [Related]
19. Plasma and cerebrospinal fluid alpha1-antichymotrypsin levels in Alzheimer's disease: correlation with cognitive impairment.
DeKosky ST; Ikonomovic MD; Wang X; Farlow M; Wisniewski S; Lopez OL; Becker JT; Saxton J; Klunk WE; Sweet R; Kaufer DI; Kamboh MI
Ann Neurol; 2003 Jan; 53(1):81-90. PubMed ID: 12509851
[TBL] [Abstract][Full Text] [Related]
20. Both plasma retinol-binding protein and haptoglobin precursor allele 1 in CSF: candidate biomarkers for the progression of normal to mild cognitive impairment to Alzheimer's disease.
Jung SM; Lee K; Lee JW; Namkoong H; Kim HK; Kim S; Na HR; Ha SA; Kim JR; Ko J; Kim JW
Neurosci Lett; 2008 May; 436(2):153-7. PubMed ID: 18378077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
